Background/aim: Age-related cataract is the most important visual impairment all over the world. Epigenetic modifications, especially overexpression of histone deacetylases, have become the focus of interest for cataract development in recent years. Sirtuin 1 (SIRT1), a class II histone deacetylase and a member of the sirtuin family, is one of the best-characterized histone deacetylases and has a pivotal role in age-related diseases. However, the association of SIRT1 with age-related cataracts has not yet been fully elucidated. Therefore, we aimed to determine the expression of SIRT1 in age-related cataract patients. Materials and methods: Expressions of SIRT1 were evaluated by quantitative polymerase chain reaction (qPCR) in patients and healthy controls. RNA samples were collected from the anterior capsule and peripheral blood samples of age-related cataract patients. Human lens epithelial cell line B3 and peripheral blood samples of healthy subjects were used as controls. Results: We determined that the expression of SIRT1 in blood and anterior capsule samples increased significantly compared to the control group (P < 0.05). Conclusion: The expression level of SIRT1 plays a vital role in the development of age-related cataract and it can be used as a biomarker. Thus, SIRT1 inhibitors can be used in the treatment of age-related cataract disease.
15 February 2023 in Egyptian Journal of Medical Human Genetics
Background: The human lens develops age-related cataracts (ARCs) because of the complicated effects of aging and stressful conditions. Under conditions involving oxidative stress, cells form stress granules (SGs). TDRD7 has been identified as an RNA granule component and an important component of SGs. TDRD7 plays a role in the post-transcriptional expression of genes, such as the crystallin gene CRYBB3. Therefore, the present study investigated TDRD7 and CRYBB3 mRNA expressions in relation to age-related cortico-nuclear cataracts. Methods: Quantitative real-time PCR was used to determine the expression levels of TDRD7 and CRYBB3 in 52 patients with ARC and 52 healthy controls. Anterior lens capsules and peripheral blood samples from patients with ARC were included in the patient group, and peripheral blood samples from healthy subjects and human lens epithelial cells (HLE-B3) were included in the control group. Gene expression levels in the different age groups were compared. Correlation analysis was used to assess the gene expression levels and age. Results: The expression of TDRD7 and CRYBB3 was significantly up-regulated (P < 0.0001) in anterior lens capsules compared to that in HLE-B3 cells. Similarly, the expression of TDRD7 (P = 0.0004) and CRYBB3 (P < 0.0001) was higher in the peripheral blood samples of patients with ARC than in those of healthy subjects. Significant upregulation (P < 0.05) was observed in the 71–81-year age group of patients. No correlation was found between gene expression levels and age. Conclusion: Significantly higher expression levels of TDRD7 and CRYBB3 in patients with ARC than in controls suggest that TDRD7 and CRYBB3 are associated with the development of age-related cortico-nuclear cataracts and the aging process under chronic stress.
The distribution of factor V Leiden G1691A, factor II G20210A, MTHFR C677T, and factor V H1299R polymorphisms known to predispose to thrombophilia in 215 cases and 40 controls admitted with indication of recurrent pregnancy loss (RPL) was investigated. Genotyping was performed by melting curve analysis using simultaneous PCR (RT-PCR). There was no difference between genotype and allele frequencies in the case and control groups in terms of the polymorphisms examined (p>0.05). In the genotype distribution of the Factor V gene G1691A polymorphism, 12.6% GA in the case group and 90.0% GG (wild) genotypes in the control group were found to be higher than the other genotypes. In the genotype distribution of the factor II gene G20210A polymorphism, the GG (wild) genotype was found to be higher in 94.5% and 97.5%, respectively, in the case group and control group than the other genotypes. In the genotype distribution of MTHFR gene C677T polymorphism, 43.7% CC (wild) in the case group and 40.0% CT genotype in the control group were found to be higher than the other genotypes. In the genotype distribution of the factor V gene A4070G polymorphism, 87.4% AA (wild) in the case group and 80% AA (wild) genotype in the control group were found to be higher than the other genotypes. However, the frequency of risk allele A for factor V Leiden G1691A (6.8% and 5%), the frequency of risk allele A for factor II gene G20210A (3% and 1.2%), MTHFR gene C677T were determined in the case and control groups. The frequency of the T allele (35.9% and 42.5%), which is the risk allele for A4070G, and the frequency of the G allele (6.5% and 16.6%), which is the risk allele for the factor V gene A4070G, were determined. When our study results were evaluated, no relationship was found between RPL and factor V Leiden G1691A, factor II G20210A, MTHFR C677T, and factor V A4070G polymorphisms.
Amaç: Kronik miyeloid lösemi (KML), BCR/ABL1 füzyon geninden kaynaklanan en yaygın hematolojik malignitelerden biridir. KML'li hastalar genellikle bazofili ve nötrofili içeren lökositoz gösterirler. KML'nin doğrulanması genellikle BCR/ABL1 füzyonunun saptanmasına dayanır. KML şüphesi olan hastalarda BCR/ABL1 p210 testi için periferik kan (PK) diferansiyeli ve tam kan sayımının (TKS) etkisini araştırmayı amaçlıyoruz. Metot: BCR/ABL1 p210 füzyonu için ilk kez test edilen hastaların retrospektif bir değerlendirmesini yaptık. Kliniğimiz veri tabanından 235 hastanın klinik ve laboratuvar bulgularını elde ettik. BCR/ABL1 p210 füzyonu, kantitatif Gerçek Zamanlı Polimeraz Zincir Reaksiyonu (RT-qPCR) ile tespit edilmiştir. Sürekli verilerin karşılaştırılması için t-testi veya Mann-Whitney U testleri uyguladık. Her parametre için alıcı çalışma karakteristiğini (ROC eğrileri) çizdik ve ROC eğrisi altındaki alanı (AUC) hesapladık. Bulgular: 235 hastanın 25'ine (%10.6) yeni KML tanısı kondu. KML hastalarında, diferansiyel ile önemli ölçüde artmış beyaz kan hücresi sayısı (WBC) vardı. Mutlak bazofil sayısı, 0,3 × 103/uL'lik bir kesme değerine sahip olan 0,829'luk ROC eğrisi (AUC) değerinin altındaki en yüksek alanı gösterdi. KML vakalarının %76,00'ında mutlak bazofil sayısı ≥0,3 × 103/uL iken, KML olmayan vakaların %95,24'ünde mutlak bazofil sayısı <0,3 × 103/uL idi. Sonuç: Sonuçlarımız, ≥0,3 × 103/uL mutlak bazofil sayısının BCR/ABL1 p210 test istemini iyileştirmeye ve sağlık hizmeti maliyetlerini düşürmeye yardımcı olabileceğini göstermektedir. Objective: Chronic myeloid leukemia (CML) is one of the most common hematological malignancies derived from the BCR/ABL1 fusion gene. Patients with CML generally manifest leukocytosis with basophilia and neutrophilia. The verification of CML is often based on the detection of BCR/ABL1 fusion. We aimed to investigate the impact of peripheral blood (PB) differential and complete blood count (CBC) on BCR/ABL1 p210 test ordering in patients with suspected CML. Methods: We performed a retrospective assessment of patients tested for the first time for BCR/ABL1 p210 fusion. We obtained clinical and laboratory findings of 235 patients from the database of our clinic. BCR/ABL1 p210 fusion was detected by quantitative real-time polymerase chain reaction (RT-qPCR). We implemented t-tests or Mann–Whitney U tests for the comparison of continuous data. We plotted the receiver operating characteristic (ROC curves) and calculated the area under the ROC curve (AUC) for each parameter. Results: Among 235 patients, 25 (%10.6) received a new diagnosis of CML. CML patients had significantly increased white blood cell count (WBC) with differential. Absolute basophil count showed the highest area under the ROC curve (AUC) value of 0.829, which had a cut-off value of 0.3 × 103/ µL. 76.00% of CML cases had an absolute basophil count of ≥0.3 × 103/µL, while 95.24% of the non-CML cases had an absolute basophil count of <0.3 × 103/µL. Conclusions: Our results indicate that an absolute basophil count of ≥0.3 × 103/µL can help improve BCR/ABL1 p210 test ordering and reduce healthcare costs.